Meeting
2021 Gastrointestinal Cancers Symposium
Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma.
Authors
Geoffrey Yuyat Ku
Memorial Sloan Kettering Cancer Center, New York, NY
Geoffrey Yuyat Ku , Abraham Jing-Ching Wu , Smita Sihag , Bernard J. Park , David Randolph Jones , Ping Gu , Steven Brad Maron , Ryan Sugarman , Sree Bhavani Chalasani , Marina Shcherba , Lara Feder , Kendall Cowie , Jaclyn Norris , Valerie Johnson , Laura H. Tang , David H. Ilson , Yelena Y. Janjigian , Daniela Molena
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Esophageal and Gastric Cancer
Track
Esophageal and Gastric Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02962063
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 226)
DOI
10.1200/JCO.2021.39.3_suppl.226
Abstract #
226
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma.
First Author: Michele Ly
Poster
2022 ASCO Annual Meeting
Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma: Final results.
First Author: Darren Cowzer
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 1b/II study of durvalumab (D) and tremelimumab (T) plus PET-adjudicated chemoradiation (CRT) in patients (Pts) with esophageal adenocarcinoma.
First Author: Geoffrey Yuyat Ku
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Network meta-analysis of global trials of 1L therapies in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.
First Author: Manish A. Shah